(2025). Evaluation of Topical Spironolactone 5% Gel Versus Eflornithine 13.9 % Cream in Treatment of Idiopathic Hirsutism: A Clinical Trial. The Egyptian Journal of Hospital Medicine, 100(1), 3680-3686. doi: 10.21608/ejhm.2025.447693
. "Evaluation of Topical Spironolactone 5% Gel Versus Eflornithine 13.9 % Cream in Treatment of Idiopathic Hirsutism: A Clinical Trial". The Egyptian Journal of Hospital Medicine, 100, 1, 2025, 3680-3686. doi: 10.21608/ejhm.2025.447693
(2025). 'Evaluation of Topical Spironolactone 5% Gel Versus Eflornithine 13.9 % Cream in Treatment of Idiopathic Hirsutism: A Clinical Trial', The Egyptian Journal of Hospital Medicine, 100(1), pp. 3680-3686. doi: 10.21608/ejhm.2025.447693
Evaluation of Topical Spironolactone 5% Gel Versus Eflornithine 13.9 % Cream in Treatment of Idiopathic Hirsutism: A Clinical Trial. The Egyptian Journal of Hospital Medicine, 2025; 100(1): 3680-3686. doi: 10.21608/ejhm.2025.447693
Evaluation of Topical Spironolactone 5% Gel Versus Eflornithine 13.9 % Cream in Treatment of Idiopathic Hirsutism: A Clinical Trial
Background: Hirsutism is defined as excessive growth of terminal hair (THs) in androgen-dependent regions. It is essential to consider a woman’s menopausal status when evaluating the cause of hirsutism. Topical eflornithine has been shown to improve hair reduction. Spironolactone acts by competing for androgen receptors in hair follicles. Objectives: The current study aimed to evaluate the efficacy of topical spironolactone 5% gel versus those of topical eflornithine 13.9% cream in the management of idiopathic hirsutism. Patients and methods: This randomized controlled trial included 58 patients with idiopathic hirsutism who were divided into two groups, Group 1 included 29 hirsute females treated with topical spironolactone gel 5% applied twice daily for 6 months and Group 2 included 29 hirsute females treated with topical eflornithine 13.9% cream applied twice daily for 6 months. Patients underwent scoring according to the Ferriman-Gallwey (F-G) scale for hirsutism before the start of treatment, during follow-up and at the end of the study. Results: Regarding F-G score before treatment, the mean scores were comparable between both groups (Group 1: 11.52, Group 2: 10.59), while after treatment, the mean scores significantly decreased in both groups (Group 1: 7.48, Group 2: 7.62). In addition, group 1 showed a significantly lower score after treatment compared with group 2. Group 1 had a higher mean percent improvement in the Ferriman-Gallwey scores and higher satisfaction scores compared to Group 2. Conclusion: It could be concluded that both topical spironolactone 5% gel and eflornithine 13.9% cream are effective options for managing idiopathic hirsutism and show a significant decrease in Ferriman-Gallwey scores after treatment, with group 1 reporting higher satisfaction scores and higher mean percent improvement.
View on SCiNiTO
Top